199 related articles for article (PubMed ID: 24239623)
1. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
[TBL] [Abstract][Full Text] [Related]
2. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
3. X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor.
Elkins JM; Wang J; Deng X; Pattison MJ; Arthur JS; Erazo T; Gomez N; Lizcano JM; Gray NS; Knapp S
J Med Chem; 2013 Jun; 56(11):4413-21. PubMed ID: 23656407
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.
Deng X; Yang Q; Kwiatkowski N; Sim T; McDermott U; Settleman JE; Lee JD; Gray NS
ACS Med Chem Lett; 2011 Mar; 2(3):195-200. PubMed ID: 21412406
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
6. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
Kuss M; Adamopoulou E; Kahle PJ
J Neurochem; 2014 Jun; 129(6):980-7. PubMed ID: 24479685
[TBL] [Abstract][Full Text] [Related]
7. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
8. Triazolopyridazine LRRK2 kinase inhibitors.
Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.
Myers SM; Miller DC; Molyneux L; Arasta M; Bawn RH; Blackburn TJ; Cook SJ; Edwards N; Endicott JA; Golding BT; Griffin RJ; Hammonds T; Hardcastle IR; Harnor SJ; Heptinstall AB; Lochhead PA; Martin MP; Martin NC; Newell DR; Owen PJ; Pang LC; Reuillon T; Rigoreau LJM; Thomas HD; Tucker JA; Wang LZ; Wong AC; Noble MEM; Wedge SR; Cano C
Eur J Med Chem; 2019 Sep; 178():530-543. PubMed ID: 31212132
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
[TBL] [Abstract][Full Text] [Related]
11. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway.
Sun W; Kesavan K; Schaefer BC; Garrington TP; Ware M; Johnson NL; Gelfand EW; Johnson GL
J Biol Chem; 2001 Feb; 276(7):5093-100. PubMed ID: 11073940
[TBL] [Abstract][Full Text] [Related]
12. Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation.
Cameron SJ; Malik S; Akaike M; Lerner-Marmarosh N; Yan C; Lee JD; Abe J; Yang J
J Biol Chem; 2003 May; 278(20):18682-8. PubMed ID: 12637502
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
[TBL] [Abstract][Full Text] [Related]
14. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
15. Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis.
Pi X; Yan C; Berk BC
Circ Res; 2004 Feb; 94(3):362-9. PubMed ID: 14670836
[TBL] [Abstract][Full Text] [Related]
16. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor.
Kato Y; Tapping RI; Huang S; Watson MH; Ulevitch RJ; Lee JD
Nature; 1998 Oct; 395(6703):713-6. PubMed ID: 9790194
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6
Ferguson FM; Liu Y; Harshbarger W; Huang L; Wang J; Deng X; Capuzzi SJ; Muratov EN; Tropsha A; Muthuswamy S; Westover KD; Gray NS
J Med Chem; 2020 Jul; 63(14):7817-7826. PubMed ID: 32530623
[TBL] [Abstract][Full Text] [Related]
18. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
19. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
20. ERK5 kinase activity is dispensable for cellular immune response and proliferation.
Lin EC; Amantea CM; Nomanbhoy TK; Weissig H; Ishiyama J; Hu Y; Sidique S; Li B; Kozarich JW; Rosenblum JS
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11865-11870. PubMed ID: 27679845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
